These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6431206)

  • 1. [In vitro activity of azthreonam (SQ 26.776) against Gram-negative bacteria].
    Landínez RJ; García Castro MA; Coladas N; Bratos MA; Kastanos N; Alvarez Alonso E
    Med Clin (Barc); 1984 Jan; 82(3):106-9. PubMed ID: 6431206
    [No Abstract]   [Full Text] [Related]  

  • 2. [In vitro activity of azthreonam on hospital Gram-negative bacilli. Results of a multicenter study].
    Deforges L; Le Van Thoi J; Soussy CJ; Duval J; Thabaut A; Meyran M; Acar JF; Kitzis MD; Chanal M; Cluzel M; Morel C
    Pathol Biol (Paris); 1983 Jun; 31(6):488-91. PubMed ID: 6348655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of Ro 17-2301, a new monobactam antibiotic].
    Roy C; Foz A; Segura C; Tirado M; Teixell M
    Med Clin (Barc); 1985 Jun; 85(5):183-6. PubMed ID: 3927089
    [No Abstract]   [Full Text] [Related]  

  • 4. [A study of the in vitro sensitivity of Enterobacteriaceae and Pseudomonas aeruginosa to 7 antimicrobial agents].
    Lynch MB; Mimica I; Valenzuela MC; Vilches A; Abarca S
    Rev Med Chil; 1972 Jan; 100(1):14-5. PubMed ID: 4622217
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro sensitivity pattern of gram negative pathogens to nalidixic acid.
    Chitkara YK
    Indian J Pathol Bacteriol; 1969 Oct; 12(4):162-8. PubMed ID: 4990210
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro susceptibilities of mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients against azthreonam, netilmicin and piperacillin.
    Flournoy DJ; Cox FR
    Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):487-9. PubMed ID: 6439964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of bacterial sensitivity in a Lambaréné hospital (Gabon)].
    Burchard GD; Wolff T
    Med Trop (Mars); 1985; 45(3):265-9. PubMed ID: 3934496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro studies of tobramycin sensitivity of bacterial strains isolated from children treated in the Institute for Mother and Child].
    Duroś H; Nowakowska K
    Probl Med Wieku Rozwoj; 1982; 11():117-20. PubMed ID: 6817325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of gentamicin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to aminoglycoside antibiotics.
    Ramírez-Ronda CH; Nevárez M; Gutiérrez-Núñez JJ; Reyes Y
    Bol Asoc Med P R; 1983 Jul; 75(7):305-7. PubMed ID: 6442865
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro selections of resistant strains by quinolones.
    López-Bartolomé O; Avial CR; Picazo JJ; Cabronero MC; Campos E
    J Chemother; 1989 Jul; 1(4 Suppl):371-3. PubMed ID: 16312445
    [No Abstract]   [Full Text] [Related]  

  • 11. [Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
    Honderlick P; Gravisse J; Dardelle D; Cahen P
    Pathol Biol (Paris); 2007 Dec; 55(10):475-7. PubMed ID: 17904768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases.
    Livermore DM; Williams JD
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():29-37. PubMed ID: 6799480
    [No Abstract]   [Full Text] [Related]  

  • 13. Azthreonam: in vitro activity against urinary pathogens.
    Lang SD; McKenzie D
    Pathology; 1983 Apr; 15(2):159-60. PubMed ID: 6412200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria.
    Percival A; Thomas E; Hart CA; Karayiannis P
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():49-55. PubMed ID: 6799482
    [No Abstract]   [Full Text] [Related]  

  • 15. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
    Dudley MN; Ambrose PG; Bhavnani SM; Craig WA; Ferraro MJ; Jones RN;
    Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azthreonam activity against gram-negative bacilli.
    Bremner DA
    Chemotherapy; 1984; 30(1):44-8. PubMed ID: 6537908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tobramycin. In vitro action of a new aminoside. Comparative study in 2 hospital centers].
    Morel C; Freymuth F; Nevot P; Kazmierczak A; Philippon A; Paul G
    Nouv Presse Med; 1973 May; 2(18):1219-23. PubMed ID: 4197620
    [No Abstract]   [Full Text] [Related]  

  • 19. Ofloxacin: in-vitro activity against clinical isolates.
    Grima P
    Chemioterapia; 1985 Dec; 4(6):434-5. PubMed ID: 3938347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study of the sensitivity of 1030 hospital-isolated bacterial strains to aztreonam.
    Grassi L
    Chemioterapia; 1984 Aug; 3(4):262-6. PubMed ID: 6543433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.